Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CURX

Curanex Pharmaceuticals Inc

Apr 30 • 10:22AM ET

0.4159

+0.0019 0.46 %

Healthcare • Biotechnology • USA • Nano • NASD

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.15	Insider Own	69.26%	Shs Outstand	28.34M	Perf Week	-6.14%
Market Cap	11.79M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	8.72M	Perf Month	-18.66%
Enterprise Value	7.17M	PEG	-	EPS next Q	-	Inst Own	1.50%	Short Float	0.58%	Perf Quarter	24.15%
Income	-4.23M	P/S	-	EPS this Y	-	Inst Trans	27.18%	Short Ratio	0.01	Perf Half Y	-45.32%
Sales	0.00M	P/B	1.05	EPS next Y	-	ROA	-69.85%	Short Interest	0.05M	Perf YTD	25.80%
Book/sh	0.40	P/C	2.37	EPS next 5Y	-	ROE	-72.09%	52W High	9.18 -95.47%	Perf Year	-
Cash/sh	0.18	P/FCF	-	EPS past 3/5Y	-1359.45% -	ROIC	-36.92%	52W Low	0.26 58.74%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.55% 11.86%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-1047.69%	Oper. Margin	-	ATR (14)	0.05	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	81.93	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	42.93	Recom	-
Dividend Gr. 3/5Y	- -	Current Ratio	81.93	EPS Q/Q	-2112.24%	SMA20	-8.21%	Beta	-	Target Price	-
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-4.61%	Rel Volume	0.01	Prev Close	0.41
Employees	-	LT Debt/Eq	0.02	Earnings	-	SMA200	-60.67%	Avg Volume	4.32M	Price	0.42
IPO	Aug 26, 2025	Option/Short	No / Yes	EPS/Sales Surpr.	- -	Trades		Volume	3,886	Change	0.46%

Apr-08-26 07:47AM	Curanex Highlights Five Additional Patient Cases Further Supporting the Potential of Its Lead Candidate in Cancer Cachexia, Advanced Cancer Supportive Care and Severe Systemic Decline (GlobeNewswire)
Apr-06-26 09:17AM	Curanex Highlights Patient Case Study Supporting Potential of Phyto-N in Cancer Cachexia and Advanced Cancer Supportive Care (GlobeNewswire) +7.94%
Apr-02-26 08:07AM	Curanex Expands Its Drug Development Pipeline to Include Cancer Cachexia, Representing a Multi-Billion-Dollar Market Opportunity and Important Step In The Company's Evolution Into a Broader Therapeutics Development Company (GlobeNewswire)
Mar-30-26 05:35PM	Curanex Provides Business Update in Connection with 2025 Annual Report as Phyto-N Advances Toward Planned IND Submission (GlobeNewswire)
Mar-18-26 08:00AM	Curanex Achieves Key Preclinical Milestone with Favorable Toxicology Profile at Maximum Dose, Advancing Toward IND Submission (GlobeNewswire) +10.43%
09:30AM	Loading…
Mar-12-26 09:30AM	Curanex Expands Scientific Advisory Board With Two Distinguished Researchers (GlobeNewswire) -11.59%
Mar-11-26 08:00AM	Curanex Appoints Two Veteran Industry Leaders to Scientific Advisory Board (GlobeNewswire) +6.16%
Mar-05-26 08:00AM	Curanex Forms World Class Scientific Advisory Board (GlobeNewswire)
Feb-26-26 02:11AM	What's Behind Curanex Pharmaceuticals (CURX) 56% Surge After Hours (Benzinga) +45.77%
Feb-25-26 08:00AM	Curanex Provides Operational Update on Key Regulatory Milestones (GlobeNewswire)
Oct-22-25 07:00AM	Curanex Pharmaceuticals Inc. Engages Strategic Investor Relations to Enhance Investor Communications and Engagement (GlobeNewswire) +14.39%
Sep-12-25 02:46PM	Curanex Pharmaceuticals Inc. Announces Exercise of the Over-Allotment Option by Underwriters (GlobeNewswire)
Aug-27-25 05:00PM	Curanex Pharmaceuticals Inc. Announces Closing of its Initial Public Offering (GlobeNewswire) +15.92% +11.37%
Aug-26-25 07:30AM	Curanex Pharmaceuticals Inc. Announces Pricing of its Initial Public Offering (GlobeNewswire)

Curanex Pharmaceuticals, Inc. engages in the pharmaceutical business. It focuses on developing and commercializing botanical treatments for inflammatory diseases. The company was founded by Ying Jing and Chang Liu in 1996 and is headquartered in Jericho, NY.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CURX

Curanex Pharmaceuticals Inc

Upgrade your Finviz experience